GLPwatch
Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment.
Bioconjug Chem · 2016
Last updated 2026-05-28Researchers created a new version of the GLP-1 drug exendin-4, called Abextide II, by attaching it to a modified dye molecule. In tests on mice with type 2 diabetes, Abextide II lowered blood sugar levels for a longer time than Albiglutide, an FDA-approved GLP-1 drug.
AI summary of the abstract below.
| Journal | Bioconjug Chem, 2016 |
|---|---|
| Citations | 29 |
| Relative citation ratio | 1.09 |
| NIH percentile | 53 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
In the treatment of type 2 diabetes mellitus, it is very important to develop therapeutics with prolonged circulation half-life. Exendin-4 is a glucagon like peptide-1 receptor (GLP-1R) agonist that has been modified in different ways for imaging insulinoma and for treating type-2 diabetes. In this work, we synthesized a maleimide derivative of truncated Evans blue dye (MEB-C3-Mal) to conjugate with (Cys(40))exendin-4 to obtain a highly stable MEB-C3-(Cys(40))exendin-4 (denoted as Abextide II). Through in situ binding with endogenous albumin, Abextide II lowers blood glucose level and prolongs the hypoglycemic effect in a type 2 diabetes mouse model more than the FDA approved Albiglutide.
Verbatim abstract via PubMed 26641886 ↗